The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues

Journal of Endocrinological Investigation

Volumn 33, Issue 9, 2010, Pages 663-670

  De Martino, M C ^a   Auriemma, R S ^a   Brevetti, G ^a   Vitale, G ^b   Schiano, V ^a   Galdieroi, M ^a   Grasso, L ^a   Lombardi, G ^a   Colao, A ^a   Pivonello, R ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acromegaly; Cardiovascular risk; Echo cloppler; Flow mediated dilation; FMD; GH; GH receptor antagonist; IGF; IMT; Intima media thickness; Pegvisomant

Indexed keywords

GLUCOSE; INSULIN; LIPID; PEGVISOMANT; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BODY MASS; BRACHIAL ARTERY; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTRANSAMINASEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; OUTCOME ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ACROMEGALY; ADULT; BLOOD VESSELS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; DRUG RESISTANCE; FEMALE; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, SOMATOTROPIN; RISK FACTORS; SOMATOSTATIN;

EID: 78751698294     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7143     Document Type: Article

References (27)

1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
2. Wright AD, Hill DM, Lowy C, Fraser TR. (1970) Mortality in acromegaly. Q J Med 1970, 39: 1-16.
3. Colao A, Spiezia S, Cerbone G, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 2001, 54: 515-24.
4. Otsuki M, Kasayama S, Yamamoto H, et al. (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 2001, 54: 791-6.
5. Chanson P, Megnien JL, del Pino M, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol (Oxf) 1998, 49: 725-31.
6. Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab 2002, 87: 3174-9.
7. Schiavon F, Maffei P, Martini C, et al. Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab 1999, 84: 3151-5.
8. Maison P, Démolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 2000, 53: 445-51.
9. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003, 58: 169-76.
10. Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intimamedia thickness in patients with acromegaly. Eur J Endocrinol 2002, 146: 303-9.
11. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154: 467-77.
12. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf) 2002, 56: 303-11.
13. Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 2007, 92: 476-82.
14. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002, 87: 1692-9.
15. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342: 1171-7. (Pubitemid 30211048)
16. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358: 1754-9.
17. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
18. Dilley RJ, Schwartz SM. Vascular remodeling in the growth hormone transgenic mouse. Circ Res 1989, 65: 1233-40.
19. Andersson IJ, Johansson ME, Wickman A, et al. Endothelial dysfunction in growth hormone transgenic mice. Clin Sci (Lond) 2006, 110: 217-25.
20. Bohlooly YM, Carlson L, Olsson B, et al. Vascular function and blood pressure in GH transgenic mice. Endocrinology 2001, 142: 3317-23.
21. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993, 6: 260S-70S.
22. Cohen R, Chanson P, Bruckert E, et al. Effects of octreotide on lipid metabolism in acromegaly. Horm Metab Res 1992, 24: 397-400.
23. Ho KK, Jenkins AB, Furier SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992, 36: 271-9.
24. Møller N, Schmitz O, Jøorgensen JO, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992, 74: 1012-9.
25. Oscarsson J, Wiklund O, Jakobsson KE, Petruson B, Bengtsson BA. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clin Endocrinol (Oxf) 1994, 41: 603-8.
26. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005, 90: 5684-91. (Pubitemid 41415476)
27. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005, 90: 5627-31.